Ray of hope in Merck cost-cutting gloom: New cancer-immunotherapy data

While headlines focused on Merck's ($MRK) 8,500-job, $2.5 billion restructuring yesterday, the pharma giant quietly posted promising early-stage data on what has become its brightest pipeline prospect: the cancer immunotherapy MK-3475. Report

Suggested Articles

After Trump's "Buy American" executive order for essential medicines, the pharma industry is pushing back.

The U.S. is slamming the brakes on its $765 million loan to Kodak amid insider trading allegations and questions about its fitness for the job.

When it comes to COVID-19 vaccines and treatments, more news is good news. That’s the latest takeaway from consumer sentiment tracking by Harris Poll.